



OPEN ACCESS

EDITED AND REVIEWED BY
Francesco Patti,
University of Catania, Italy

*CORRESPONDENCE

Xuan Feng
✉ xfeng@neurology.bsd.uchicago.edu
Anthony T. Reder
✉ areder@neurology.bsd.uchicago.edu

†These authors have contributed equally to this work and share first authorship

RECEIVED 23 June 2023
ACCEPTED 27 June 2023
PUBLISHED 08 August 2023

CITATION

Fong CC, Spencer J, Howlett-Prieto Q, Feng X and Reder AT (2023) Corrigendum: Adaptive and innate immune responses in multiple sclerosis with anti-CD20 therapy: gene expression and protein profiles. *Front. Neurol.* 14:1245622. doi: 10.3389/fneur.2023.1245622

COPYRIGHT

© 2023 Fong, Spencer, Howlett-Prieto, Feng and Reder. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Adaptive and innate immune responses in multiple sclerosis with anti-CD20 therapy: gene expression and protein profiles

Chloe C. Fong[†], Julian Spencer[†], Quentin Howlett-Prieto, Xuan Feng* and Anthony T. Reder*

Department of Neurology, University of Chicago Medicine, Chicago, IL, United States

KEYWORDS

anti-CD20 therapy, B cell, multiple sclerosis, ocrelizumab, T cell, TLR

A corrigendum on

[Adaptive and innate immune responses in multiple sclerosis with anti-CD20 therapy: gene expression and protein profiles](#)

by Fong, C. C., Spencer, J., Howlett-Prieto, Q., Feng, X., and Reder, A. T. (2023). *Front. Neurol.* 14:1158487. doi: 10.3389/fneur.2023.1158487

In the published article, there was an error. The level of CD79B RNA at 2 weeks was typed incorrectly in the text.

A correction has been made to **Results**, “*Expression of B-cell-related genes relevant to MS is downregulated after ocrelizumab infusion*,” paragraph 1. This sentence previously stated:

“Genes included *CD79A* (fold-change at 2 weeks vs. time 0 = -272; at 6 months vs. time 0 = -172; not shown in figure because of extreme scale of change) and *CD79B* (-2.47; and -2.46) (Figure 4A).”

The corrected sentence appears below:

“Genes included *CD79A* (fold-change at 2 weeks vs. time 0 = -272; at 6 months vs. time 0 = -172; not shown in figure because of extreme scale of change) and *CD79B* (-55.0; and -2.46) (Figure 4A).”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.